Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$34.27

-1.94 (-5.36%)

07:02
10/10/16
10/10
07:02
10/10/16
07:02

Alnylam: DMC recommends continuation of APOLLO Phase 3 trial

Alnylam Pharmaceuticals announced that the Data Monitoring Committee, or DMC, for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy met on October 7, 2016 and recommended continuation of the trial without modification. The APOLLO DMC met at the request of the company following the decision - announced on October 5, 2016 - to discontinue development of revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy. The DMC will continue to meet periodically per their remit to monitor the overall safety of patisiran in the APOLLO study through its completion. The APOLLO study has completed enrollment of 225 patients at 44 sites in 19 countries, between December 2013 and January 2016.

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$34.27

-1.94 (-5.36%)

10/07/16
MSCO
10/07/16
DOWNGRADE
Target $36
MSCO
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz downgraded Alnylam Pharmaceuticals after the company discontinued development of revusiran. The analyst removed Alnylam from its model and cut its price target to $36 from $93 on shares.
10/07/16
MSCO
10/07/16
DOWNGRADE
MSCO
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Morgan Stanley
10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded on reduced competition, valuation at BMO Capital
As noted earlier, BMO Capital upgraded Ionis (IONS) to Outperform from Market Perform. After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, BMO Capital analyst Do Kim expects Ionis to benefit from the reduced competition. Kim recommends buying Ionis' stock on weakness today. Target to $48 from $42.
10/06/16
COWN
10/06/16
NO CHANGE
Target $100
COWN
Outperform
Alnylam price target lowered to $100 from $150 at Cowen
Cowen analyst Ritu Baral noted Alnylam announced the discontinuation of revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy due to risk/benefit and safety signals. The analyst does not believe it signals any risk to the platform, as other programs have shown solid safety. Baral said revusiran was a minor driver so she maintained her Outperform rating and lowered her price target to $100 from $150 on Alnylam shares.

TODAY'S FREE FLY STORIES

ALNY

Alnylam

$42.25

1.445 (3.54%)

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Hot Stocks
Breaking Hot Stocks news story on Alnylam »

Dodge & Cox reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

$NYE

NYSE Market Internals

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVO

Cenveo

$6.84

-0.16 (-2.29%)

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Hot Stocks
Breaking Hot Stocks news story on Cenveo »

Brigade Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Technical Analysis
NASDAQ market internals summary »

Volume is very heavy for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$1.33

-0.04 (-2.92%)

16:15
12/09/16
12/09
16:15
12/09/16
16:15
Hot Stocks
Cellectar, INC Research enter into Work Order »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$14.40

0.86 (6.35%)

16:12
12/09/16
12/09
16:12
12/09/16
16:12
Hot Stocks
Breaking Hot Stocks news story on International Seaways »

Cyrus Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFS

Saul Centers

$66.45

-0.96 (-1.42%)

16:09
12/09/16
12/09
16:09
12/09/16
16:09
Hot Stocks
Saul Centers raises quarterly dividend 8.5% to 51c from 47c per share »

The dividend is to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASNA

Ascena Retail

$8.04

-0.07 (-0.86%)

16:08
12/09/16
12/09
16:08
12/09/16
16:08
Hot Stocks
Ascena Retail names David Jaffe chairman of the board »

Ascena Retail announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MORN

Morningstar

16:08
12/09/16
12/09
16:08
12/09/16
16:08
Hot Stocks
Morningstar raises quarterly dividend to 23c from 22c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAND

Sandstorm Gold

$3.83

-0.19 (-4.73%)

16:07
12/09/16
12/09
16:07
12/09/16
16:07
Syndicate
Breaking Syndicate news story on Sandstorm Gold »

Sandstorm Gold files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIU

AC Immune

$14.93

2.88 (23.90%)

, RHHBY

Roche

$27.86

0.78 (2.88%)

16:05
12/09/16
12/09
16:05
12/09/16
16:05
Hot Stocks
AC Immune partner Genentech presents 'important' data on Alzheimer's therapy »

AC Immune (ACIU)…

ACIU

AC Immune

$14.93

2.88 (23.90%)

RHHBY

Roche

$27.86

0.78 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDVX

Medovex

$1.50

0.03 (2.04%)

16:03
12/09/16
12/09
16:03
12/09/16
16:03
Hot Stocks
Breaking Hot Stocks news story on Medovex »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$78.79

-1.69 (-2.10%)

16:01
12/09/16
12/09
16:01
12/09/16
16:01
Hot Stocks
Belden extends shareholder rights agreement »

Belden announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GENE

Genetic Technologies

$1.19

-0.01 (-0.83%)

15:59
12/09/16
12/09
15:59
12/09/16
15:59
Hot Stocks
Breaking Hot Stocks news story on Genetic Technologies »

CVI Investments reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLO

Flowers Foods

$19.26

2.2325 (13.11%)

15:53
12/09/16
12/09
15:53
12/09/16
15:53
Recommendations
Flowers Foods analyst commentary  »

Flowers Foods settlement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$54.22

-0.21 (-0.39%)

15:50
12/09/16
12/09
15:50
12/09/16
15:50
Options
Halliburton Dec 48.5 puts for a nickel per contract »

Halliburton Dec 48.5 puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BIIB

Biogen

$289.54

4.24 (1.49%)

15:43
12/09/16
12/09
15:43
12/09/16
15:43
Recommendations
Biogen analyst commentary  »

Piper says Biogen still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLO

Valero

$67.84

-0.535 (-0.78%)

15:40
12/09/16
12/09
15:40
12/09/16
15:40
Options
Higher option volume in Valero driven by downside put purchases »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKLN

Skyline Medical

$2.94

-0.01 (-0.34%)

15:36
12/09/16
12/09
15:36
12/09/16
15:36
Syndicate
Skyline Medical files to sell 1.925M units »

Each unit consisting of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$4.26

-0.08 (-1.84%)

15:35
12/09/16
12/09
15:35
12/09/16
15:35
Hot Stocks
Farnsworth acquires 1.74M Helios and Matheson shares as part of merger pact »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLO

Flowers Foods

$19.10

2.07 (12.16%)

15:32
12/09/16
12/09
15:32
12/09/16
15:32
Upgrade
Flowers Foods rating change  »

Flowers Foods upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$84.28

-0.71 (-0.84%)

, RAD

Rite Aid

$8.20

0.045 (0.55%)

15:25
12/09/16
12/09
15:25
12/09/16
15:25
Periodicals
Walgreens near finalizing Rite Aid divestiture package, CTFN reports »

Walgreens (WBA) is…

WBA

Walgreens Boots Alliance

$84.28

-0.71 (-0.84%)

RAD

Rite Aid

$8.20

0.045 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

BAS

Basic Energy

$0.44

-0.0039 (-0.89%)

15:19
12/09/16
12/09
15:19
12/09/16
15:19
Hot Stocks
Breaking Hot Stocks news story on Basic Energy »

Basic Energy trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
12/09/16
12/09
15:16
12/09/16
15:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:16
12/09/16
12/09
15:16
12/09/16
15:16
Technical Analysis
NASDAQ market internals summary »

Volume is heavy for this…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.